naltrexone has been researched along with nifedipine in 15 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 4 (26.67) | 18.2507 |
2000's | 5 (33.33) | 29.6817 |
2010's | 6 (40.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Topliss, JG; Yoshida, F | 1 |
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
Lombardo, F; Obach, RS; Waters, NJ | 1 |
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
Ekins, S; Williams, AJ; Xu, JJ | 1 |
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Chavkin, C; Gibbs, SM; Simmons, ML; Terman, GW | 1 |
Amico, MC; Morrone, LA; Romanelli, L; Valeri, P | 1 |
Duncan, MJ; Elde, RP; Gurwell, JA; Hauser, KF; Maderspach, K; Stiene-Martin, A | 1 |
Ahmed, MS; Cemerikic, B; Zamah, R | 1 |
Cousins, MJ; Fink, DJ; Hao, S; Iwasaki, H; Mamiya, K; Mata, M; Takahata, O | 1 |
1 review(s) available for naltrexone and nifedipine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
14 other study(ies) available for naltrexone and nifedipine
Article | Year |
---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
L-type calcium channels mediate dynorphin neuropeptide release from dendrites but not axons of hippocampal granule cells.
Topics: Animals; Axons; Calcium Channel Blockers; Calcium Channels; Dendrites; Dynorphins; Guinea Pigs; Hippocampus; Isradipine; Long-Term Potentiation; Naltrexone; Nifedipine; omega-Conotoxin GVIA; Peptides; Receptors, Opioid, kappa | 1995 |
Withdrawal contractures of guinea-pig isolated ileum after acute activation of kappa-opioid receptors.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Clonidine; Guinea Pigs; Ileum; In Vitro Techniques; Male; Morphine; Muscle Contraction; Muscle, Smooth; Naloxone; Naltrexone; Nifedipine; Pyrrolidines; Receptors, Opioid, kappa; Substance Withdrawal Syndrome | 1993 |
kappa-opioid receptor expression defines a phenotypically distinct subpopulation of astroglia: relationship to Ca2+ mobilization, development, and the antiproliferative effect of opioids.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Analgesics; Animals; Astrocytes; Benzeneacetamides; Bromodeoxyuridine; Calcium; Calcium Channel Blockers; Cell Count; Cell Division; Cells, Cultured; DNA; Enzyme Inhibitors; Gene Expression Regulation, Developmental; Immunohistochemistry; Mice; Mice, Inbred ICR; Naloxone; Naltrexone; Narcotic Antagonists; Narcotics; Nifedipine; Phenotype; Pyrrolidines; Receptors, Opioid, kappa; Thapsigargin; Time Factors | 1996 |
Identification of L-type calcium channels associated with kappa opioid receptors in human placenta.
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; Benzeneacetamides; Calcium Channel Agonists; Calcium Channel Blockers; Calcium Channels; Calcium Signaling; Cell Membrane; Chorionic Gonadotropin; Chorionic Villi; Culture Techniques; Egtazic Acid; Female; Humans; Isradipine; Naltrexone; Nifedipine; Placenta; Pyrrolidines; Receptors, Opioid, kappa; Trophoblasts | 1998 |
Nifedipine potentiates the antinociceptive effect of endomorphin-1 microinjected into the periaqueductal gray in rats.
Topics: Analgesics, Opioid; Animals; Area Under Curve; Behavior, Animal; Calcium Channel Blockers; Dose-Response Relationship, Drug; Male; Microinjections; Naltrexone; Narcotic Antagonists; Nifedipine; Oligopeptides; Pain Measurement; Periaqueductal Gray; Rats; Rats, Sprague-Dawley; Reaction Time | 2003 |